title: Progression-free survival remains debatable endpoint in cancer trials.
authors.forename: Rabiya
authors.initials: R
authors.lastname: Tuma
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents